D.A. Davidson & CO. decreased its position in Cerus Co. (NASDAQ:CERS) by 53.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,882 shares of the biotechnology company’s stock after selling 32,512 shares during the quarter. D.A. Davidson & CO.’s holdings in Cerus were worth $146,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in CERS. California Public Employees Retirement System increased its position in shares of Cerus by 8.1% during the second quarter. California Public Employees Retirement System now owns 127,628 shares of the biotechnology company’s stock worth $851,000 after acquiring an additional 9,528 shares during the period. Teachers Advisors LLC increased its position in shares of Cerus by 3.2% during the third quarter. Teachers Advisors LLC now owns 312,076 shares of the biotechnology company’s stock worth $2,250,000 after acquiring an additional 9,702 shares during the period. Prudential Financial Inc. increased its position in shares of Cerus by 110.2% during the third quarter. Prudential Financial Inc. now owns 25,403 shares of the biotechnology company’s stock worth $183,000 after acquiring an additional 13,320 shares during the period. Raymond James Trust N.A. purchased a new stake in shares of Cerus during the fourth quarter worth $71,000. Finally, First Quadrant L P CA purchased a new stake in shares of Cerus during the third quarter worth $112,000. 61.05% of the stock is currently owned by institutional investors.
A number of analysts have recently weighed in on CERS shares. Zacks Investment Research raised Cerus from a “hold” rating to a “buy” rating and set a $6.50 price objective on the stock in a research report on Monday, February 4th. BidaskClub lowered Cerus from a “sell” rating to a “strong sell” rating in a research report on Wednesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 price objective on shares of Cerus in a research report on Tuesday, December 18th. Finally, ValuEngine lowered Cerus from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 12th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $8.50.
Cerus stock opened at $6.41 on Thursday. Cerus Co. has a twelve month low of $3.95 and a twelve month high of $8.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.17 and a current ratio of 3.48. The firm has a market cap of $852.13 million, a PE ratio of -11.45 and a beta of 1.41.
ILLEGAL ACTIVITY WARNING: This story was first reported by Macon Daily and is the property of of Macon Daily. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://macondaily.com/2019/02/14/cerus-co-cers-shares-sold-by-d-a-davidson-co.html.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.
See Also: Discount Rate
Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERS).
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.